Katarína Rašlová, Jozef Lacka
Obesity is an important health and social problem. It is a significant risk factor for emergence of type 2 diabetes mellitus. Overweight and obesity accelerate the manifestation of macrovascular and microvascular complications in type 2. diabetes. However, pharmacological therapy of DM 2 is often associated with weight increase. New therapy with GLP 1 (glucagon like peptide 1) analogue improves glucose metabolism as well as decrease body weight in type 2 diabetics. Preclinical trials showed that exogenous GLP 1 decreases appetite, energy intake and delays stomach emptying. In the clinical program LEAD, liraglutide showed significant effect on glycemic control associated with clinically significant weight reduction. Weight reduction is associated with decrease in adipose tissue, mainly visceral fat. In all trials of the LEAD program the therapy with liraglutide was associated with significant decrease in blood pressure and a positive effect on the level of triglyceride rich lipoproteins. GLP 1 analogue - liraglutide has a complex impact on the therapy of diabetes mellitus.
Kye words: type 2. diabetes, liraglutide, obesity